Popular keywords:Autoimmune disease antibody drugs New antibody drugs Antitumor drugs
Beijing VDJBio Co., LTD. has been selected as a special board enterprise (regulatory level) by the Beijing Equity Exchange Center

Regarding the "Specialized, Refined, Unique, and New" Special Edition of the Beijing Stock Exchange:
The "Specialized, Refined, Unique, and New" Special Board of the Beijing Stock Exchange is a regional equity market characteristic board operated by the Beijing Equity Trading Center in accordance with the requirements of the "Guiding Opinions on the High Quality Construction of Regional Equity Market Specialized, Refined, Unique, and New" Special Board issued by the General Office of the China Securities Regulatory Commission and the Ministry of Industry and Information Technology, and with the approval of the China Securities Regulatory Commission, the Ministry of Industry and Information Technology, and the Beijing Municipal Government. It is led by the Beijing Municipal Bureau of Economy and Information Technology, jointly supervised by the Beijing Local Financial Supervision and Administration Bureau and the Beijing Regulatory Bureau of the China Securities Regulatory Commission. The Beijing Stock Exchange strengthens the cultivation of listed companies through optimizing financing services and empowering capital operations. Provide a one-on-one listing "green channel" for companies listed on the board, ensuring that there are no "bottlenecks" in the listing process at critical junctures, and promoting it efficiently and smoothly. Through institutional linkage mechanisms and convenient communication mechanisms, the listing cycle of enterprises can be shortened by more than 30%, accelerating the speed of cultivating enterprise listings.

Regarding Weidejie Biotechnology:
Beijing VDJBio Co., LTD. is a national high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Beijing. Focusing on the development of the best innovative antibody drugs in the field of autoimmune diseases. The company completed its Series C financing in April 2023 and is currently undergoing a Pre IPO round. After completing this round of financing, the company will actively promote the process of applying for an IPO on the Beijing Stock Exchange.
Beijing VDJBio Co., LTD.

Mobile website

Follow us
Copyright © 2022 vdjbio.com All Rights Reserved. Beijing VDJBio Co., LTD. 京ICP备17050725号-1
Screenshot, WeChat recognition QR code
WeChat ID:ceishi
(Click on WeChat to copy and add friends)